Keywords
pentoxifylline
meldonium -butyrobetaine dihydrate
How to Cite
Abstract
57 patients with myocardial ischemia on the background of chronic obstructive pulmonary diseases received general therapy, of which 28 patients in the control group were additionally receiving pentoxifylline, while 29 patients in the main group received meldonium +-butirobetaine dihydrate. Nitric oxid, cytokines, endothelin-1, platelet-vascular hemostasis were studied. Improvement in clinical manifestations of the disease was accompanied by a decrease in the level of endothelin-1, interleukin-1, tumor necrosis factor, platelet aggregation and increased nitric oxide levels. The laboratory-clinical positive changes were practically identical in both the basic and the comparison group.References
Bauer V., Sotnikova R. (2010) Nitric oxide – tne endothelium-derived relaxing factor and its role in endothelial functions. Gen. Physiol. Biophys. Dec.; 29 (4): 319–340. doi:10.4149/gpb_2010_04_319
Biletskiy S.V. (2008). Endotelial’naya disfunktsiya i patologiya serdechno-sosudistoy sistemy [Endothelial dysfunction and pathology of the cardiovascular system]. Vnutrennaya meditsina – Internal medicine. 2 (8): 36–41 [in Russian].
Ilnytskyi R.I. (2007). Osoblyvosti imunolohichnoi reaktyvnosti u khvorykh na khronichne obstruktyvne zakhvoriuvannia lehen’ [Features of immunological reactivity in patients with chronic obstructive pulmonary disease]. Ukrainskyi pulmonolohichnyi zhurnal – Ukrainian pulmonological journal. 2 (56): 21–25 [in Ukrainian].
Kalvinsh I.Ya. (2002). Mildronat – mekhanism deystviya i perspektivy ego primeneniya [Mildronate – mechanisms of action and prospects of its use]. Riga; 39 s. [in Russian].
Latoguz I.K. Zhukov V.I., Pogorelov V.N., Brek V.V. (2003). «Nemaya» ishemiya miokarad u bol’nykh legochnoy gipertenziey i ee terapiya [«Mute» myocardial ischemia in patients with pulmonary hypertension and its therapy]. Visn. probl. biolohii i medytsyny – Bulletin of Biology and Medicine. 2: 93–97 [in Russian].
Kuznetsova S.M. (Eds.) (2015). Novye vozmozhnosti antiishemicheskoy terapii i vosstanovleniya funktsii endoteliya [New opportunities for anti-ischemic therapy and recovery of endothelial function]: materially XVII Mezhdunarodnoy konferentsii «Ot patofiziologii k ratsional’noy terapii v nevrologii». aprel’ 5; Truskavets. Truskavets; 37 s. [in Russian].
Pohorelov V.M. Shelest B.O., Zaitseva O.V. (2015). Enerhetychnyi metabolism ishemii miokarda khvorykh na khronichne leheneve sertse ta yoho korektsiia [The energy metabolism of myocardial ischemia in patients with chronic pulmonary heart and its correction]. Visnyk naukovykh doslidzhen – Bulletin of scientific research. 2: 23–26 [in Ukrainian].
Rasputina L.V. (2011). Komorbidnist nespetsyfichnykh zakhvoriuvan orhaniv dyhannia ta sertsevo-sudynnoi systemy v praktytsi likaria [Comorbidity of nonspecific diseases of the respiratory and cardiovascular system in the practice of a doctor]. Ukrayinskiy pulmonolohichnyi zhurnal – Ukrainian pulmonologist magazine. 4: 25–27 [in Ukrainian].
Feshchenko Yu.I. (2012). Novaya redaktsiya rukovodstva global'noy initsiativy po khronicheskomu obstruktivnomu zabolevaniyu legkikh [New edition of the leadership of the Global Initiative for Chronic Obstructive Pulmonary Disease]. Zdorovia Ukrayiny – Health of Ukraine. 2 (18): 10–11 [in Russian].
Sin D.D., Anthonisen N.R., Soriano I.B., Agusti A.G. (2006). Mortality in CORD: vole of comorbidities. Fur. Respiv. J. 28: 1245–1257.